Walmsley, a director at Akero Therapeutics ... The shares are primarily held through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where Walmsley is a managing member of the ...
Citi analyst Jonathan Woo says Akero Therapeutics (AKRO)’ 96-week data update from its SYMMETRY trial of efruxifermin for patients with compensated cirrhosis due to metabolic dysfunction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback